

Martin Prieto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6626117/publications.pdf>

Version: 2024-02-01

187
papers

9,352
citations

46918

47
h-index

39575

94
g-index

208
all docs

208
docs citations

208
times ranked

5866
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-to the Old to the Oldest. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158.	2.3	16
2	Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk?. <i>Journal of Liver Transplantation</i> , 2021, 1, 100005.	0.2	0
3	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	1.8	72
4	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
5	Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020). <i>Gastroenterología Y Hepatología</i> , 2020, 43, 559-587.	0.2	18
6	Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1853-1853.	1.4	21
7	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 559-587.	0.0	20
8	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e493-e494.	1.8	5
9	THU-124-Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C). <i>Journal of Hepatology</i> , 2019, 70, e213-e214.	1.8	0
10	Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 267-271.	0.8	12
11	Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. <i>Transplant International</i> , 2018, 31, 649-657.	0.8	7
12	Association of Cardiac Abnormalities to the Frail Phenotype in Cirrhotic Patients on the Waitlist. <i>Transplantation</i> , 2018, 102, e101-e107.	0.5	9
13	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	2.4	83
14	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. <i>Liver International</i> , 2018, 38, 1940-1950.	1.9	15
15	Impact of hepatitis C virus (<sc>HCV</sc>) antiviral treatment on the need for liver transplantation (<sc>LT</sc>). <i>Liver International</i> , 2018, 38, 1022-1027.	1.9	20
16	Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virus-Infected Patients. <i>Liver Transplantation</i> , 2018, 24, 1476-1480.	1.3	2
17	Out of Milan criteria and worse intention to treat results at large liver transplant center. <i>Journal of Hepatology</i> , 2018, 68, S201-S202.	1.8	0
18	VI documento de consenso de la sociedad española de trasplante hepático (SETH). <i>Gastroenterología Y Hepatología</i> , 2018, 41, 406-421.	0.2	9

#	ARTICLE	IF	CITATIONS
19	VI consensus document by the Spanish Liver Transplantation Society. <i>Gastroenterología Y Hepatología</i> (English Edition), 2018, 41, 406-421.	0.0	0
20	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018, 68, S601.	1.8	3
21	VI Consensus Document by the Spanish Liver Transplantation Society. <i>Cirugía Española</i> (English) Tj ETQq1 1 0.784314 rgBT ₁ /Overl	0.1	1
22	VI documento de consenso de la sociedad española de trasplante hepático (SETH). <i>Cirugía Española</i> , 2018, 96, 326-341.	0.1	4
23	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. <i>BMC Infectious Diseases</i> , 2017, 17, 45.	1.3	17
24	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 945-949.e1.	2.4	22
25	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the HepaC registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	3.6	78
26	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	1.9	10
27	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. <i>Transplant International</i> , 2017, 30, 1041-1050.	0.8	6
28	Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry. <i>Journal of Hepatology</i> , 2017, 66, S399.	1.8	0
29	Idiosyncratic Drug-Induced Liver Injury: A 20-Year Update of the Cases Enrolled By the Spanish Dili Registry. <i>Clinical Therapeutics</i> , 2017, 39, e57.	1.1	0
30	Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice. <i>Journal of Hepatology</i> , 2017, 66, S523-S524.	1.8	0
31	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, 718-723.	1.8	90
32	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 226-237.	1.0	22
33	Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. <i>Journal of Hepatology</i> , 2017, 67, 1168-1176.	1.8	96
34	Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice “ preliminary data Vie-KinD study. <i>Journal of Hepatology</i> , 2017, 66, S718-S719.	1.8	0
35	The use of prophylactic strategies using hepatitis B immunoglobulin for hepatitis B recurrence after liver transplantation in routine clinical practice in Spain. Preliminary results of the 1st round of a delphi panel. <i>Journal of Hepatology</i> , 2017, 66, S190.	1.8	0
36	HCV cirrhosis: liver volume as a non-invasive predictor of liver recovery post DAA treatment. <i>Journal of Hepatology</i> , 2017, 66, S574.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes of patients delisted from the waiting list of liver transplantation after interferon-free antiviral therapy. <i>Journal of Hepatology</i> , 2017, 66, S186.	1.8	0
38	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. <i>PLoS ONE</i> , 2017, 12, e0184550.	1.1	45
39	Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. <i>World Journal of Gastroenterology</i> , 2017, 23, 7459-7469.	1.4	8
40	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 414-422.	0.7	21
41	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	1.3	73
42	Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. <i>Transplantation Proceedings</i> , 2016, 48, 3013-3016.	0.3	3
43	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2016, 64, S133.	1.8	8
44	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	1.8	115
45	Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C Cohort. <i>Journal of Hepatology</i> , 2016, 64, S217-S218.	1.8	8
46	Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Genotype 1, after Liver Transplantation: Efficacy and Safety. <i>Journal of Hepatology</i> , 2016, 64, S538-S539.	1.8	0
47	Peri-Transplant Treatment with Direct-Acting Antivirals of HIV-HCV Coinfected Patients. <i>Journal of Hepatology</i> , 2016, 64, S552.	1.8	0
48	Prevents HBV Reactivation with Tenofovir in Anti-HBC Positive Patients with Hematologic Malignancies Treated with Rituximab. Results Final Visit 18-Months (Preblin Study). <i>Journal of Hepatology</i> , 2016, 64, S369.	1.8	3
49	Efficacy and Tolerability of Interferon-Free Antiviral Therapy in Kidney Transplant (KT) Recipients with Chronic Hepatitis C: Real-Life Data from the Spanish National Registry (HEPA-C). <i>Journal of Hepatology</i> , 2016, 64, S793-S794.	1.8	4
50	Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4. <i>Journal of Hepatology</i> , 2016, 64, S831.	1.8	2
51	Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1364-1365.	0.2	18
52	Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection. <i>Transplantation</i> , 2016, 100, 1507-1512.	0.5	23
53	Effectiveness and Safety of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir Patients with Genotype 1 Chronic Hepatitis C Virus Infection: Results from the Spanish Real World Cohort. <i>Journal of Hepatology</i> , 2016, 64, S218-S219.	1.8	7
54	Efficacy and Clinical Impact of Daclatasvir-Based Antiviral Therapy in Severe Recurrent Hepatitis C after Liver Transplantation. Results from a Multicenter Spanish Group. <i>Journal of Hepatology</i> , 2016, 64, S547.	1.8	1

#	ARTICLE	IF	CITATIONS
55	Treatment Discontinuation after HBsAg Loss is Safe in Chronic Hepatitis B Patients Treated with Nucleos/Tide Analogs: A Retrospective Multicenter Study (HEBESAS). <i>Journal of Hepatology</i> , 2016, 64, S588.	1.8	0
56	Ledipasvir/Sofosbuvir for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Spanish Multicentre Experience. <i>Journal of Hepatology</i> , 2016, 64, S794-S795.	1.8	1
57	Effectiveness of Daclatasvir Based Therapy in Patients with Chronic Hepatitis C in Europe: Experience from the Named Patient Program. <i>Journal of Hepatology</i> , 2016, 64, S801.	1.8	2
58	Interferon (INF)-Free Antiviral Therapy in Cirrhotic Patients Infected with Hepatitis C on the Waiting List for Liver Transplantation. Efficacy and Impact on Delisting and Liver Function. <i>Journal of Hepatology</i> , 2016, 64, S543.	1.8	4
59	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 779-789.	1.1	25
60	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 685-697.	4.6	402
61	Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis. <i>Annals of Hepatology</i> , 2016, 15, 939-943.	0.6	15
62	P1097 : Distinguishing drug induced autoimmune hepatitis from idiopathic autoimmune hepatitis. <i>Journal of Hepatology</i> , 2015, 62, S761.	1.8	1
63	Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. <i>Liver Transplantation</i> , 2015, 21, 812-822.	1.3	39
64	Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin. <i>Transplant Infectious Disease</i> , 2015, 17, 208-220.	0.7	9
65	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 2015, 61, 1485-1494.	3.6	206
66	P0649 : Characterization of HBsAg loss in patients with chronic hepatitis B (CHB) treated with nucleos/tide analogs (NUCs): A retrospective multicenter study (HEBESAS). <i>Journal of Hepatology</i> , 2015, 62, S563-S564.	1.8	1
67	P0654 : Long-term sustained suppression of viral replication is associated with low HBsAg levels in patients with chronic hepatitis B (CHB) treated with nucleos(T)ide analogues (NUCs). <i>Journal of Hepatology</i> , 2015, 62, S565-S566.	1.8	0
68	P0785 : First real clinical practice data in Spain on sofosbuvir, simeprevir and daclatasvir in post-transplant HCV recurrence: The HepatiC registry experience. <i>Journal of Hepatology</i> , 2015, 62, S626.	1.8	0
69	Distinguishing Drug-induced Autoimmune Hepatitis from idiopathic Autoimmune Hepatitis and DILI with Autoantibodies. <i>Clinical Therapeutics</i> , 2015, 37, e115-e116.	1.1	0
70	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	0.8	4
71	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 116-125.	1.9	95
72	Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. <i>Liver Transplantation</i> , 2014, 20, 25-34.	1.3	31

#	ARTICLE	IF	CITATIONS
73	Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 159-168.	1.0	18
74	P1198 EFFECTIVENESS OF TRIPLE THERAPY IN CLINICAL PRACTICE FOR TREATMENT-NAIVE HCV PATIENTS WITH ADVANCED HEPATIC FIBROSIS. VIROLOGIC RESPONSE DATA AT 12 WEEKS POST-TREATMENT (SVR-12W). <i>Journal of Hepatology</i> , 2014, 60, S486-S487.	1.8	0
75	P1040 TENOFOVIR FOR THE PROPHYLAXIS OF HBV REACTIVATION IN ANTI-HBC-POSITIVE PATIENTS WITH HEMATOLOGIC MALIGNANCIES TREATED WITH RITUXIMAB: PRELIMINARY RESULTS OF A RANDOMIZED STUDY (PREBLIN STUDY). <i>Journal of Hepatology</i> , 2014, 60, S421-S422.	1.8	4
76	O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2014, 60, S26.	1.8	25
77	P1200 EFFECTIVENESS OF TRIPLE THERAPY WITH BOCEPREVIR OR TELAPREVIR IN A MULTICENTRE CLINICAL PRACTICE COHORT OF HCV TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED HEPATIC FIBROSIS. SVR-12W AFTER TREATMENT. <i>Journal of Hepatology</i> , 2014, 60, S488.	1.8	1
78	The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2014, 28, 84-91.	1.2	65
79	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.	0.6	248
80	P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH "LATIN-AMERICAN DILI REGISTRY. <i>Journal of Hepatology</i> , 2014, 60, S169.	1.8	0
81	P1196 ADVERSE EFFECTS OF TRIPLE THERAPY WITH BOCEPREVIR (BOC) AND TELAPREVIR (TVR) IN CLINICAL PRACTICE IN PATIENTS WITH ADVANCED HEPATIC FIBROSIS. <i>Journal of Hepatology</i> , 2014, 60, S485-S486.	1.8	0
82	P1041 TENOFOVIR MONOTHERAPY VERSUS LAMIVUDINE PLUS ADEFOVIR IN LAMIVUDINE-FAILURE PATIENTS RESCUED WITH LAMIVUDINE PLUS ADEFOVIR COMBINATION: INTERIM ANALYSIS OF THE TENOSIMP-B CLINICAL TRIAL. <i>Journal of Hepatology</i> , 2014, 60, S422.	1.8	1
83	P1207 TRIPLE THERAPY FOR HCV CIRRHOSIS IN LIVER TRANSPLANT CANDIDATES. HIGH RATE OF PREVENTION OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT) IN WELL SELECTED PATIENTS. <i>Journal of Hepatology</i> , 2014, 60, S490.	1.8	1
84	P910 IMPACT OF ANEMIA IN VIRAL RESPONSE DURING TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2014, 60, S378.	1.8	0
85	P1143 APPLICABILITY OF TRIPLE THERAPY IN CIRRHOTIC POPULATION: VALIDATION OF CUPIC DATA. <i>Journal of Hepatology</i> , 2014, 60, S463.	1.8	0
86	P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. <i>Journal of Hepatology</i> , 2014, 60, S169.	1.8	0
87	Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study. <i>Journal of Hepatology</i> , 2014, 61, 1020-1028.	1.8	90
88	P894 PROPHYLAXIS OF DE NOVO HEPATITIS B VIRUS INFECTION WITH LAMIVUDINE IN HBsAg-NEGATIVE NAIVE RECIPIENTS OF HEPATITIS B CORE ANTIBODY-POSITIVE LIVERS: A 13-YEAR SINGLE-CENTER EXPERIENCE. <i>Journal of Hepatology</i> , 2014, 60, S372.	1.8	0
89	Long-term outcome of "long-term liver transplant survivors". <i>Transplant International</i> , 2013, 26, 740-750.	0.8	53
90	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach. <i>Liver Transplantation</i> , 2013, 19, 69-77.	1.3	18

#	ARTICLE	IF	CITATIONS
91	236 SEXUAL DYSFUNCTION IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2013, 58, S101-S102.	1.8	0
92	915 WORSE TOLERABILITY OF TRIPLE THERAPY IN SPECIAL POPULATIONS: CIRRHOTICS AND LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2013, 58, S377.	1.8	0
93	1225 TOLERABILITY TO ANTIVIRAL DUAL AND TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2013, 58, S497.	1.8	0
94	Chronic Kidney Disease After Liver Transplantation. <i>Transplantation</i> , 2013, 95, 1148-1153.	0.5	35
95	Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. <i>Annals of Hepatology</i> , 2013, 12, 974-978.	0.6	9
96	Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation. <i>Annals of Hepatology</i> , 2013, 12, 274-281.	0.6	12
97	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 999.	0.8	16
98	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 535-542.	0.8	25
99	195 LONG-TERM OUTCOME OF LIVER TRANSPLANTATION FOR HEPATITIS B WITH ANTI-HBC POSITIVE GRAFTS. <i>Journal of Hepatology</i> , 2012, 56, S83-S84.	1.8	0
100	Comparison of two non-contemporaneous HCV-liver transplant cohorts: Strategies to improve the efficacy of antiviral therapy. <i>Journal of Hepatology</i> , 2012, 56, 1310-1316.	1.8	42
101	Hepatitis C virus viral kinetics during $\hat{I}_{\pm-2a}$ or $\hat{I}_{\pm-2b}$ pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. <i>Journal of Clinical Virology</i> , 2012, 53, 231-238.	1.6	7
102	New concepts and best practices for management of pre- and post-transplantation cancer. <i>Transplantation Reviews</i> , 2012, 26, 261-279.	1.2	82
103	Management of hepatitis B virus infection in the pre-transplant setting. <i>Digestive and Liver Disease Supplements</i> , 2011, 5, 10-14.	0.2	0
104	517 POST-LIVER TRANSPLANTATION (LT) OUTCOME IN HIV/HCV CO-INFECTED PATIENTS. COMPARISON WITH MONOINFECTED PATIENTS WITH HCV-CIRRHOSIS. <i>Journal of Hepatology</i> , 2011, 54, S212.	1.8	0
105	521 PATIENTS SURVIVING AT LEAST 10 YEARS POST LIVER TRANSPLANTATION: LONG TERM COMPLICATIONS. <i>Journal of Hepatology</i> , 2011, 54, S213-S214.	1.8	0
106	540 VALIDATION OF A PREDICTIVE MODEL FOR CHRONIC RENAL DYSFUNCTION FOLLOWING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S221.	1.8	0
107	806 TRIPHASIC VIRAL LOAD KINETICS OF HEPATITIS C VIRUS DURING ANTIVIRAL THERAPY POST-TRANSPLANTATION: EFFECT OF THE TYPE OF PEGYLATED-IFN AND BASELINE IMMUNOSUPPRESSION. <i>Journal of Hepatology</i> , 2011, 54, S323-S324.	1.8	0
108	Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. <i>Liver Transplantation</i> , 2011, 17, 1318-1327.	1.3	13

#	ARTICLE	IF	CITATIONS
109	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011, 53, 62-72.	3.6	274
110	Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study. <i>Transplantation</i> , 2011, 92, 334-340.	0.5	34
111	Effect of Calcineurin Inhibitors in the Outcome of Liver Transplantation in Hepatitis C Virus-Positive Recipients. <i>Transplantation</i> , 2010, 90, 1204-1209.	0.5	62
112	Indications and results of liver retransplantation: experience with 1181 patients in the hospital universitario La Fe. <i>CirugÃa EspaÃ±ola (English Edition)</i> , 2010, 87, 356-363.	0.1	1
113	94 CALCINEURIN INHIBITORS AND OUTCOME OF LIVER TRANSPLANTATION IN HCV-POSITIVE RECIPIENTS: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Hepatology</i> , 2010, 52, S43.	1.8	2
114	450 LOW EFFICACY OF ANTIVIRAL THERAPY IN HCV-LIVER TRANSPLANT RECIPIENTS TREATED AT ADVANCED STAGES OF FIBROSIS. <i>Journal of Hepatology</i> , 2010, 52, S183.	1.8	0
115	451 NO IMPACT OF OBESITY ON POST-LIVER TRANSPLANTATION OUTCOME AMONG HCV-INFECTED LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2010, 52, S183.	1.8	1
116	490 IMPACT OF OBESITY ON SURVIVAL IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2010, 52, S198.	1.8	0
117	Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. <i>Liver Transplantation</i> , 2009, 15, 79-87.	1.3	60
118	Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis. <i>Liver Transplantation</i> , 2009, 15, 738-746.	1.3	65
119	Antibody to hepatitis B core antigen-positive grafts: Not perfect but no longer marginal. <i>Liver Transplantation</i> , 2009, 15, 1164-1168.	1.3	9
120	Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. <i>Liver Transplantation</i> , 2009, 15, 1798-1807.	1.3	20
121	Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior. <i>Liver Transplantation</i> , 2009, 15, 1709-1717.	1.3	24
122	Indications for and Results of Liver Retransplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1016-1017.	0.3	12
123	923 SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S335-S336.	1.8	6
124	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. <i>Liver Transplantation</i> , 2008, 14, 1449-1460.	1.3	101
125	Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 679-687.	2.6	269
126	74 THE ANTIVIRAL RESPONSE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IS COMPARABLE IN LAMIVUDINE (LAM)-NAIVE AND LAM-EXPERIENCED SUBJECTS TREATED FOR CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2008, 48, S33.	1.8	6

#	ARTICLE	IF	CITATIONS
127	227 LONG-TERM RESULTS WITH THE USE OF GRAFTS FROM HBSAG NEGATIVE HBCAB POSITIVE DONORS IN LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2008, 48, S93.	1.8	32
128	Adherence to Lamivudine After an Early Withdrawal of Hepatitis B Immune Globulin Plays an Important Role in the Long-Term Prevention of Hepatitis B Virus Recurrence. <i>Transplantation</i> , 2007, 84, 650-654.	0.5	94
129	Gastrointestinal Complications in Liver Transplant Recipients: MITOS Study. <i>Transplantation Proceedings</i> , 2007, 39, 2311-2313.	0.3	46
130	[137] RESPONSE TO PEGYLATED INTERFERON-RIBAVIRIN IN PATIENTS WITH RECURRENT HEPATITIS C IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR MIXED (ALCOHOL-HCV) CIRRHOSIS. <i>Journal of Hepatology</i> , 2007, 46, S62.	1.8	1
131	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	1.3	239
132	Lessons learned from anatomic variants of the hepatic artery in 1,081 transplanted livers. <i>Liver Transplantation</i> , 2007, 13, 1401-1404.	1.3	106
133	127 Liver transplantation for HCV-alcohol aetiology: Is the outcome similar to those to HCV or alcohol alone?. <i>Journal of Hepatology</i> , 2006, 44, S56-S57.	1.8	0
134	129 The five year follow-up of a randomized study comparing lamivudine with lamivudine+HBIG investigating the prevention of HBV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2006, 44, S57.	1.8	4
135	Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. <i>Journal of Hepatology</i> , 2006, 44, 717-722.	1.8	170
136	Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. <i>Transplant International</i> , 2006, 19, 641-648.	0.8	24
137	Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation. <i>Journal of Viral Hepatitis</i> , 2006, 13, 104-115.	1.0	13
138	Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. <i>Liver Transplantation</i> , 2006, 12, 762-767.	1.3	81
139	Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2006, 12, 1067-1076.	1.3	154
140	Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. <i>Liver Transplantation</i> , 2005, 11, 456-462.	1.3	63
141	Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post-Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus. <i>Transplantation Proceedings</i> , 2005, 37, 3960-3962.	0.3	34
142	De Novo Internal Neoplasms after Liver Transplantation: Increased Risk and Aggressive Behavior in Recent Years?. <i>American Journal of Transplantation</i> , 2004, 4, 596-604.	2.6	123
143	Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2004, 10, 217-227.	1.3	19
144	Budd-Chiari syndrome caused by membranous obstruction of the inferior vena cava associated with coeliac disease. <i>Digestive and Liver Disease</i> , 2004, 36, 157-162.	0.4	23

#	ARTICLE	IF	CITATIONS
145	102 Preliminary data for the treatment of adefovir in transplant patients with hepatitis B (HBV) resistant to lamivudine. <i>Journal of Hepatology</i> , 2004, 40, 38.	1.8	0
146	422 Efficacy and safety of adefovir for the treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine in Spain. <i>Journal of Hepatology</i> , 2004, 40, 125.	1.8	0
147	Recurrent hepatitis C genotype 1b following liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1207-1212.	0.8	37
148	Validation and refinement of survival models for liver retransplantation. <i>Hepatology</i> , 2003, 38, 460-469.	3.6	114
149	Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. <i>Liver Transplantation</i> , 2003, 9, 228-235.	1.3	104
150	Delayed onset of severe hepatitis C-related liver damage following liver transplantation: A matter of concern?. <i>Liver Transplantation</i> , 2003, 9, 1152-1158.	1.3	47
151	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. <i>Hepatology</i> , 2003, 38, 1419-1427.	3.6	190
152	A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2003, 38, 811-817.	1.8	184
153	Prolonged follow-up of HBV liver transplanted patients: results from a randomized study comparing lamivudine vs. lamivudine+HBIG in the prevention of HBV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2003, 38, 37.	1.8	1
154	Genetic heterogeneity in immunogenic epitopes of the hepatitis C virus NS3 protein in liver transplant recipients with recurrent hepatitis C. <i>Journal of Hepatology</i> , 2003, 38, 114.	1.8	0
155	Potential reduction of post-transplantation HCV-related disease progression by a better selection of the donor. <i>Journal of Hepatology</i> , 2002, 36, 175-176.	1.8	0
156	Severe recurrent hepatitis C following liver transplantation (OLT): treatment with combination interferon-ribavirin therapy (CT). <i>Journal of Hepatology</i> , 2002, 36, 187.	1.8	0
157	Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. <i>Hepatology</i> , 2002, 36, 202-210.	3.6	566
158	Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. <i>Liver Transplantation</i> , 2002, 8, 1020-1027.	1.3	47
159	De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. <i>Liver Transplantation</i> , 2001, 7, 51-58.	1.3	181
160	Liver transplantation in patients with portal vein thrombosis. <i>Liver Transplantation</i> , 2001, 7, 125-131.	1.3	164
161	Are posttransplantation protocol liver biopsies useful in the long term?. <i>Liver Transplantation</i> , 2001, 7, 790-796.	1.3	122
162	Famciclovir Treatment in Transplant Recipients With Hbv-Related Liver Disease: Disappointing Results. <i>American Journal of Gastroenterology</i> , 2001, 96, 526-533.	0.2	14

#	ARTICLE	IF	CITATIONS
163	Alarming decrease in patient survival among HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2001, 34, 32-33.	1.8	1
164	Natural History of Clinically Compensated Hepatitis C Virus-Related Graft Cirrhosis After Liver Transplantation. <i>Hepatology</i> , 2000, 32, 852-858.	3.6	505
165	HCV-related fibrosis progression following liver transplantation: increase in recent years. <i>Journal of Hepatology</i> , 2000, 32, 673-684.	1.8	723
166	Post-transplantation (LT) significant HCV-related disease severity: Increase in recent years. <i>Journal of Hepatology</i> , 2000, 32, 34.	1.8	1
167	Does HLA matching influence accelerated progression of hepatitis C following liver transplantation in genotype 1b infection?. <i>Journal of Hepatology</i> , 2000, 32, 51.	1.8	34
168	Hepatocellular carcinoma (HCC): Can it still be considered a controversial indication for liver transplantation (LT)?. <i>Journal of Hepatology</i> , 2000, 32, 53.	1.8	0
169	Are post-transplantation protocol liver biopsies useful in the longterm. <i>Journal of Hepatology</i> , 2000, 32, 53.	1.8	0
170	Retransplant of the liver (RLT) in recurrent hepatitis C virus (HCV) infection: Retrospective multicentric study. <i>Journal of Hepatology</i> , 2000, 32, 55.	1.8	0
171	High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. <i>Hepatology</i> , 1999, 29, 250-256.	3.6	504
172	Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. <i>Liver Transplantation</i> , 1999, 5, 246-248.	1.9	38
173	Incidence and outcome of De Novo malignancies after liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 1275-1277.	0.3	44
174	Comparative analysis of quantification of viral load in patients infected with hepatitis C virus: quantiplex HCV RNA assay and amplicor monitor assay. <i>Revista Espanola De Enfermedades Digestivas</i> , 1999, 91, 569-82.	0.1	1
175	Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. <i>Journal of Hepatology</i> , 1998, 28, 756-763.	1.8	163
176	Liver transplantation in hepatitis C. A Spanish multi-centre experience. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 771-776.	0.8	56
177	OUTCOME OF AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION ¹ . <i>Transplantation</i> , 1998, 66, 1645-1650.	0.5	139
178	Hyperlipidemia in liver transplant recipients: Prevalence and risk factors. <i>Liver Transplantation</i> , 1997, 3, 416-422.	1.9	87
179	Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications. <i>Revista Espanola De Enfermedades Digestivas</i> , 1997, 89, 531-50.	0.1	1
180	Does the healthy hepatitis C virus carrier state really exist? an analysis using polymerase chain reaction. <i>Hepatology</i> , 1995, 22, 413-417.	3.6	102

#	ARTICLE	IF	CITATIONS
181	Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction*1. Hepatology, 1995, 22, 413-417.	3.6	11
182	Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology, 1995, 22, 413-7.	3.6	70
183	Hepatitis C Viral Infection after Orthotopic Liver Transplantation. Advances in Experimental Medicine and Biology, 1994, 368, 173-179.	0.8	6
184	Bacteriuria in patients with cirrhosis. Journal of Hepatology, 1992, 16, 73-76.	1.8	29
185	Prospective assessment of donor blood screening for antibody to hepatitis B core antigen as a means of preventing posttransfusion non-A, non-B, hepatitis. Hepatology, 1989, 9, 449-451.	3.6	22
186	Diagnosis of malignant ascites. Digestive Diseases and Sciences, 1988, 33, 833-838.	1.1	41
187	Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Journal of Hepatology, 1985, 1, 573-578.	1.8	76